These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12820439)

  • 1. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
    Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
    Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
    Welsh SJ; Bellamy WT; Briehl MM; Powis G
    Cancer Res; 2002 Sep; 62(17):5089-95. PubMed ID: 12208766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells.
    Horiuchi A; Imai T; Shimizu M; Oka K; Wang C; Nikaido T; Konishi I
    Anticancer Res; 2002; 22(5):2697-702. PubMed ID: 12529984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
    Sivridis E; Giatromanolaki A; Gatter KC; Harris AL; Koukourakis MI;
    Cancer; 2002 Sep; 95(5):1055-63. PubMed ID: 12209691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis.
    Giatromanolaki A; Sivridis E; Maltezos E; Athanassou N; Papazoglou D; Gatter KC; Harris AL; Koukourakis MI
    Arthritis Res Ther; 2003; 5(4):R193-201. PubMed ID: 12823854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
    Kurebayashi J; Otsuki T; Kurosumi M; Soga S; Akinaga S; Sonoo H
    Jpn J Cancer Res; 2001 Dec; 92(12):1342-51. PubMed ID: 11749701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma.
    Valković T; Dobrila F; Melato M; Sasso F; Rizzardi C; Jonjić N
    Virchows Arch; 2002 Jun; 440(6):583-8. PubMed ID: 12070596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
    Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
    Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
    Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.